Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine, Tainan City, Taiwan.
Acta Neurol Scand. 2014 Jan;129(1):41-8. doi: 10.1111/ane.12143. Epub 2013 Jun 13.
Statin therapy has demonstrated benefits in ischemic stroke patients. However, little is known about whether the timing of statin initiation affects clinical outcomes. The possible association of statin use and cerebral hemorrhage is also a concern for early statin therapy after stroke. The objective of this study was to evaluate the efficacy and safety of the initiation timing of statins in acute ischemic stroke.
A cohort study was performed using 5-year National Health Insurance Research Database in Taiwan. Patients without prior statin therapy admitted for their new ischemic stroke or transient ischemic attack (TIA) were enrolled. Patients were recognized as inhospital use group (2019 patients, statin initiation during hospitalization), intermediate use group (2266 patients, statin initiation within 1 year after discharge) or late use group (2958 patients, statin initiation 1 year later after discharge). The study endpoint was the composite outcome of ischemic stroke, TIA, hemorrhagic stroke, or acute coronary event.
As compared with inhospital use, patients with late use had a 49% increased risk (adjusted HR: 1.49, 95% CI: 1.26-1.76) of composite endpoint. In contrast, patients with intermediate use had similar risk of endpoint as those with inhospital use. The risk of cerebral hemorrhage was similar in patients receiving inhospital, intermediate, or late statin treatment.
In acute ischemic stroke, patients receiving late statin treatment carried a poorer clinical outcome than those with earlier statin initiation. Inhospital statin use after an acute ischemic stroke did not increase the risk of cerebral hemorrhage.
他汀类药物治疗已被证明对缺血性脑卒中患者有益。然而,对于他汀类药物治疗开始时间是否影响临床结局,目前知之甚少。早期脑卒中后开始他汀类药物治疗可能会增加脑出血的风险,这也是一个令人关注的问题。本研究旨在评估急性缺血性脑卒中患者开始他汀类药物治疗的时机的疗效和安全性。
本研究使用了台湾 5 年国家健康保险研究数据库进行了队列研究。纳入了无既往他汀类药物治疗史,因新发缺血性卒中和短暂性脑缺血发作(TIA)入院的患者。将患者识别为住院期间使用组(2019 例,住院期间开始他汀类药物治疗)、中期使用组(2266 例,出院后 1 年内开始他汀类药物治疗)或晚期使用组(2958 例,出院后 1 年以上开始他汀类药物治疗)。研究终点为缺血性卒中和 TIA、脑出血或急性冠脉事件的复合结局。
与住院期间使用相比,晚期使用患者的复合终点风险增加了 49%(调整后的 HR:1.49,95%CI:1.26-1.76)。相比之下,中期使用患者的终点风险与住院期间使用患者相似。接受住院、中期或晚期他汀治疗的患者脑出血风险相似。
在急性缺血性脑卒中患者中,晚期开始他汀治疗的患者临床结局较差,而急性缺血性脑卒中后住院期间开始他汀类药物治疗并未增加脑出血的风险。